Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents

  Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug
                           Developments and Patents

  PR Newswire

  LONDON, February 6, 2013

LONDON, February 6, 2013 /PRNewswire/ --

Pharma stocks performed fairly well lately. However, the main concern for all
the major companies was related to the patent expiry of their blockbuster
drugs. Amgen Inc. (NASDAQ: AMGN) is about to lose its patent exclusivity for
its cancer drug Neupogen. However, the sector is also witnessing good merger
and acquisition activities, where big players are acquiring smaller companies
in order to make up the losses sustained through patent expirations.  Smaller
biotech companies are also betting big on developing drugs for various
cancers, though the prospects do not look so brigh t. StockCall analysts have
released their latest round of technical research on Amgen and Peregrine. This
free research can be accessed by signing up now at

http://www.stockcall.com/registration

Amgen Provides Optimistic Projections

Amgen recently reported positive results for the fourth quarter. Its revenue
grew 11.25 percent to $4.42 billion while its adjusted net income stood at
$1.40 per share, beating consensus estimate of $1.39 per share in quarterly
net income. Amgen expects its FY 2013 adjusted earnings to be in the range of
$6.85 and $7.15 per share, while revenue is likely to be in the range of $17.8
billion and $18.2 billion, in comparison to $17.3 billion in revenue it earned
for FY2012. Thus, while the company is likely to report better results, but
the rate of growth is likely to be a little muted. However, Amgen surpassed
consensus estimates for the projections. Register today and read our free
technical report on Amgen at

http://www.StockCall.com/AMGN020613.pdf

The company also successfully conducted phase 3 of its cancer drug Neulasta.
Amgen draws a big chunk of its revenue from Neupogen franchise. However, the
drug would go off patent protection by the end of 2013 and the loss of
exclusivity is expected to affect Amgen. Neupogen faces stiff competition from
the companies like Novartis in the markets outside of the U.S. and these
competing companies may launch their products in the U.S., causing further
damage. However, the company has somewhat strong drug candidates including
AMG145, a cholesterol drug candidate.

Amgen stock grew over 25 percent in the past 12 months. It also offers good
dividend yield of 2.17 percent. The company is likely to increase its dividend
in the future, thus offering good returns to the investors. Amgen is also
growing through acquisitions as it recently completed the purchase of
Icelandic company decode Genetics.

Peregrine Struggles with Cancer Drug Development

Peregrine Pharmaceuticals Inc. specializes in developing therapies for viral
infections. It also develops treatments for cancers. It is currently engaged
in developing treatment for non-small cell lung cancer. If successful, the
company will make big fortunes as non-small cell lung cancer accounts for
about 80 percent of lung cancer cases. However, the company does not have very
solid track record. The drug candidate bavituximab has been controversial as
it led to the stock's massive tumble in September 2012. Sign up to download
the free technical analysis on Peregrine Pharmaceuticals at

http://www.StockCall.com/PPHM020613.pdf 

Peregrine is a small company with the market capitalization of less than $300
million. The stock is quite volatile as well. The company is currently looking
to get past the phase II for bavituximab. Overall, the stock may be held if it
is already in your portfolio. On the upside, the stock is currently trading
about 50 percent below its 52-week high, thus in case of positive news on its
lung cancer drug, Peregrine stock has massive upside.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com

Contact: Contact Person: William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
 
Press spacebar to pause and continue. Press esc to stop.